Compare Braze Inc (BRZE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Inovio Pharmaceuticals Inc — how do they compare? Braze Inc trades at $26.29 (market cap $2.95B), while Inovio Pharmaceuticals Inc trades at $1.17 (market cap $95.85M). The key difference: Braze Inc is far larger — about 30.8× Inovio Pharmaceuticals Inc's market cap, and Braze Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BRZE | INO | |
|---|---|---|
Market Cap | $2.95B | $95.85M |
Sector | Technology | Health |
52-Week High | $36.19 | $2.87 |
52-Week Low | $15.79 | $1.05 |
Enterprise Value | $2.64B | $66.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $26.60, up 5.85% with strong bullish momentum. The stock shows robust revenue growth, increasing from $238M in 2022 to $593M in 2025, though profitability remains negative with a -15.51% net margin. Technical indicators show bullish moving averages but overbought RSI levels. Recent news highlights Goldman Sachs initiation and strong Q1 2027 results with accelerating revenue growth and AI-driven customer engagement tools.
Outlook remains positive with 96% analyst buy ratings and $34.78 consensus target, representing 31% upside. Key risks include persistent losses despite revenue growth and competitive pressures in customer engagement software. The company's AI capabilities and fourth straight quarter of organic revenue acceleration provide growth catalysts, but investors should monitor profitability improvements.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
